Videos
Immunotherapy for All Patients With Triple-Negative Breast Cancer
03/14/2026
At Great Debates Solid Tumors in Miami, Florida, Melinda Telli, MD, from Stanford University School of Medicine in Stanford, California, discusses whether immune checkpoint inhibitors should be used in all patients with early-stage triple-negative breast cancer.
Dr Telli reflects on nearly 5 years since pembrolizumab was introduced with neoadjuvant chemotherapy for stage II-III disease, highlighting its impact while noting remaining evidence gaps in the adjuvant setting and in stage I disease.
Source:
Telli M. All patients with TNBC should receive immune checkpoint inhibitor therapy: Yes vs no. Presented at Great Debates - Solid Tumors; Miami, Florida. March 14-15, 2026.
